完整後設資料紀錄
DC 欄位語言
dc.contributor.authorBarve, Indrajeet J.en_US
dc.contributor.authorChen, Li-Hsunen_US
dc.contributor.authorWei, Patrick C. P.en_US
dc.contributor.authorHung, Jui-Teen_US
dc.contributor.authorSun, Chung-Mingen_US
dc.date.accessioned2014-12-08T15:29:45Z-
dc.date.available2014-12-08T15:29:45Z-
dc.date.issued2013-04-01en_US
dc.identifier.issn0040-4020en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.tet.2013.01.061en_US
dc.identifier.urihttp://hdl.handle.net/11536/21370-
dc.description.abstractEnantioselective synthesis of clinically approved drug Silodosin for the treatment of benign prostatic hyperplasia from the commercially available compounds 1-acetyl-5-(2-aminopropyl) indoline-7-carbonitrile A and 2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl methanesulfonate C is explored. Key step in the synthesis is chiral resolution of intermediate I, which was achieved by a simple diastereomeric crystallization using (S)-(+)-mandelic acid assisted by ultrasonication. The present synthetic strategy has lesser number of steps and is vastly improved the overall yield in this short route towards target compound Silodosin. (C) 2013 Elsevier Ltd. All rights reserved.en_US
dc.language.isoen_USen_US
dc.titleEnantioselective synthesis of (-)-(R) Silodosin by ultrasound-assisted diastereomeric crystallizationen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.tet.2013.01.061en_US
dc.identifier.journalTETRAHEDRONen_US
dc.citation.volume69en_US
dc.citation.issue13en_US
dc.citation.spage2834en_US
dc.citation.epage2843en_US
dc.contributor.department應用化學系zh_TW
dc.contributor.departmentDepartment of Applied Chemistryen_US
dc.identifier.wosnumberWOS:000315843800020-
dc.citation.woscount1-
顯示於類別:期刊論文


文件中的檔案:

  1. 000315843800020.pdf

若為 zip 檔案,請下載檔案解壓縮後,用瀏覽器開啟資料夾中的 index.html 瀏覽全文。